ICT-107 is a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens.
Firm claims nanotechnology could lead to safer, more effective vaccines.
The companies plan to discover and validate targets that enhance Novartis’ Radioligand Therapies (RLTs) through a three-year research collaboration. Novartis will select up to three exclusive DDR targets, and receive worldwide rights on these targets for use with its RLTs, which are designed to deliver targeted radiation to a specific subset of cancer cells with minimal effect on surrounding healthy cells.
Gene therapy developers struggle to manufacture trial materials, according to U.K. group behind network of innovation centers intended to help researchers move therapies into the clinic.
Biologists at the Washington University in St. Louis are using comparative metabologenomics to try to uncover what may be “silencing” Streptomyces (the bacteria responsible for the first bacterial antibiotics to treat tuberculosis back in the 1940s) and preventing it from producing desirable compounds encoded by its genes. The study highlights comparative metabologenomics as a powerful approach to expose the features that differentiate strong antibiotic producers from weaker ones.
Rentschler's new facility, adjacent to the existing Milford, MA site, is expected to significantly expand cGMP manufacturing capacity.
Ferring will pay up to $12.7 million for on-demand alprostadil cream as Apricus prepares to resubmit NDA to FDA
Deal expands the buyer’s immuno-oncology pipeline with Cavatak® (coxsackievirus Type A21, or CVA21), which has already shown positive clinical data in combination trials